News

March 25, 2021
This money will allow for the expansion of remote recruitment of participants for this research that aims to treat the heart and help the brain
March 24, 2021
Atrial fibrillation (AF) is one of the leading causes of stroke and often goes undiagnosed due to lack of symptoms.1 It is estimated that 300,000 people are living with undiagnosed AF and that over 2,000 lives could be saved every year in England with adequate detection and treatment.2,3 Daiichi Sankyo has entered into a strategic collaboration w
March 23, 2021
The Valley Hospital has become the first center in the world to utilize leading-edge imaging software designed to enhance the safety and efficacy of a Watchman (Boston Scientific) imp
March 23, 2021
U.S. FDA has assigned a target action date of January 28, 2022. Application based on results from the Phase 3 EXPLORER-HCM trial
March 23, 2021
The trial aims to demonstrate the safety and efficiency of a leadless II pacemaker system in patients with abnormal heart rhythm
March 23, 2021
Milestone achieved as company prepares for next stage of commercial growth and expansion
March 22, 2021
A clinical study of a new cardiac ablation procedure for patients with an irregular heartbeat has launched at Beaumont Health, a worldwide leader in the treatment of atrial fibrillation, or AFib.
March 19, 2021
CathVision ApS, a medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, is announcing a change to its Board of Directors.
March 18, 2021
Transaction Unites Leading Outsourced RCM Provider with Coding & Registry Firm